Loss of exclusivityAugust 2035latest FDA-listed patent expiry
CompanyPRIOVANT THERAPEUTICS INC
Drug detail
Brand name
LISRAYA
Active ingredient
BREPOCITINIB TOSYLATE
Strength
EQ 30MG BASE
Dosage form
TABLET
Route
ORAL
Modality
Small molecule
FDA approval
August 2026
Marketing status
RX
Listed patents
Patent
Expires
Type
9663526
August 2035
substance, product
11197867
August 2035
substance, product
Regulatory exclusivity
Code
Expires
NCE
August 2031
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.